A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

NCT06023095 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the investigational drug LY3502970 in Chinese adults who are overweight or have obesity, focusing on side effects reported during the study.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 24 people

Who can join Ages 18–65 · all sexes

Timeline Started 2023-09 · est. completion 2024-07

Where 3 sites · China

What this study is testing ClinicalTrials.gov NCT06023095 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.

Treatments tested

LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.

Main thing measured	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06023095 ↗